PURPOSE: We tested the hypotheses that CHEK2*1100delC heterozygosity is associated with increased risk of early death, breast cancer-specific death, and risk of a second breast cancer in women with a first breast cancer. PATIENTS AND METHODS: From 22 studies participating in the Breast Cancer Association Consortium, 25,571 white women with invasive breast cancer were genotyped for CHEK2*1100delC and observed for up to 20 years (median, 6.6 years). We examined risk of early death and breast cancer-specific death by estrogen receptor status and risk of a second breast cancer after a first breast cancer in prospective studies. RESULTS: CHEK2*1100delC heterozygosity was found in 459 patients (1.8%). In women with estrogen receptor-positive breast cancer, multifactorially adjusted hazard ratios for heterozygotes versus noncarriers were 1.43 (95% CI, 1.12 to 1.82; log-rank P = .004) for early death and 1.63 (95% CI, 1.24 to 2.15; log-rank P < .001) for breast cancer-specific death. In all women, hazard ratio for a second breast cancer was 2.77 (95% CI, 2.00 to 3.83; log-rank P < .001) increasing to 3.52 (95% CI, 2.35 to 5.27; log-rank P < .001) in women with estrogen receptor-positive first breast cancer only. CONCLUSION: Among women with estrogen receptor-positive breast cancer, CHEK2*1100delC heterozygosity was associated with a 1.4-fold risk of early death, a 1.6-fold risk of breast cancer-specific death, and a 3.5-fold risk of a second breast cancer. This is one of the few examples of a genetic factor that influences long-term prognosis being documented in an extensive series of women with breast cancer.
PURPOSE: We tested the hypotheses that CHEK2*1100delC heterozygosity is associated with increased risk of early death, breast cancer-specific death, and risk of a second breast cancer in women with a first breast cancer. PATIENTS AND METHODS: From 22 studies participating in the Breast Cancer Association Consortium, 25,571 white women with invasive breast cancer were genotyped for CHEK2*1100delC and observed for up to 20 years (median, 6.6 years). We examined risk of early death and breast cancer-specific death by estrogen receptor status and risk of a second breast cancer after a first breast cancer in prospective studies. RESULTS: CHEK2*1100delC heterozygosity was found in 459 patients (1.8%). In women with estrogen receptor-positive breast cancer, multifactorially adjusted hazard ratios for heterozygotes versus noncarriers were 1.43 (95% CI, 1.12 to 1.82; log-rank P = .004) for early death and 1.63 (95% CI, 1.24 to 2.15; log-rank P < .001) for breast cancer-specific death. In all women, hazard ratio for a second breast cancer was 2.77 (95% CI, 2.00 to 3.83; log-rank P < .001) increasing to 3.52 (95% CI, 2.35 to 5.27; log-rank P < .001) in women with estrogen receptor-positive first breast cancer only. CONCLUSION: Among women with estrogen receptor-positive breast cancer, CHEK2*1100delC heterozygosity was associated with a 1.4-fold risk of early death, a 1.6-fold risk of breast cancer-specific death, and a 3.5-fold risk of a second breast cancer. This is one of the few examples of a genetic factor that influences long-term prognosis being documented in an extensive series of women with breast cancer.
Authors: Muriel A Adank; Marianne A Jonker; Irma Kluijt; Saskia E van Mil; Rogier A Oldenburg; Wolter J Mooi; Frans B L Hogervorst; Ans M W van den Ouweland; Johan J P Gille; Marjanka K Schmidt; Aad W van der Vaart; Hanne Meijers-Heijboer; Quinten Waisfisz Journal: J Med Genet Date: 2011-11-05 Impact factor: 6.318
Authors: Edoardo Colzani; Annelie Liljegren; Anna L V Johansson; Jan Adolfsson; Henrik Hellborg; Per F L Hall; Kamila Czene Journal: J Clin Oncol Date: 2011-09-12 Impact factor: 44.544
Authors: G H de Bock; M Schutte; E M M Krol-Warmerdam; C Seynaeve; J Blom; C T M Brekelmans; H Meijers-Heijboer; C J van Asperen; C J Cornelisse; P Devilee; R A E M Tollenaar; J G M Klijn Journal: J Med Genet Date: 2004-10 Impact factor: 6.318
Authors: Annegien Broeks; Lot de Witte; Anke Nooijen; Angelina Huseinovic; Jan G M Klijn; Flora E van Leeuwen; Nicola S Russell; Laura J van't Veer Journal: Breast Cancer Res Treat Date: 2004-01 Impact factor: 4.872
Authors: Annegien Broeks; Linde M Braaf; Angelina Huseinovic; Anke Nooijen; Jos Urbanus; Frans B L Hogervorst; Marjanka K Schmidt; Jan G M Klijn; Nicola S Russell; Flora E Van Leeuwen; Laura J Van 't Veer Journal: Breast Cancer Res Date: 2007 Impact factor: 6.466
Authors: Kristóf Arvai; Péter Horváth; Bernadett Balla; Anna M Tőkés; Bálint Tobiás; István Takács; Zsolt Nagy; Péter Lakatos; János P Kósa Journal: Fam Cancer Date: 2014-12 Impact factor: 2.375
Authors: Anne S Reiner; Julia Sisti; Esther M John; Charles F Lynch; Jennifer D Brooks; Lene Mellemkjær; John D Boice; Julia A Knight; Patrick Concannon; Marinela Capanu; Marc Tischkowitz; Mark Robson; Xiaolin Liang; Meghan Woods; David V Conti; David Duggan; Roy Shore; Daniel O Stram; Duncan C Thomas; Kathleen E Malone; Leslie Bernstein; Jonine L Bernstein Journal: J Clin Oncol Date: 2018-04-05 Impact factor: 44.544
Authors: Lothar Häberle; Alexander Hein; Matthias Rübner; Michael Schneider; Arif B Ekici; Paul Gass; Arndt Hartmann; Rüdiger Schulz-Wendtland; Matthias W Beckmann; Wing-Yee Lo; Werner Schroth; Hiltrud Brauch; Peter A Fasching; Marius Wunderle Journal: Geburtshilfe Frauenheilkd Date: 2017-06-28 Impact factor: 2.915
Authors: P A Fasching; S Y Brucker; T N Fehm; F Overkamp; W Janni; M Wallwiener; P Hadji; E Belleville; L Häberle; F-A Taran; D Lüftner; M P Lux; J Ettl; V Müller; H Tesch; D Wallwiener; A Schneeweiss Journal: Geburtshilfe Frauenheilkd Date: 2015-01 Impact factor: 2.915
Authors: Christina G Selkirk; Kristen J Vogel; Anna C Newlin; Scott M Weissman; Shelly M Weiss; Chi-Hsiung Wang; Peter J Hulick Journal: Fam Cancer Date: 2014-12 Impact factor: 2.375
Authors: Nadine Tung; Nancy U Lin; John Kidd; Brian A Allen; Nanda Singh; Richard J Wenstrup; Anne-Renee Hartman; Eric P Winer; Judy E Garber Journal: J Clin Oncol Date: 2016-03-14 Impact factor: 44.544